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Abstract 
Background: The Preferred Reporting Items for Systematic Reviews and Meta‑Analyses (PRISMA) extension state‑
ment for network meta‑analysis (NMA) published in 2015 promotes comprehensive reporting in published systematic 
reviews with NMA. PRISMA‑NMA includes 32 items: 27 core items as indicated in the 2009 PRISMA Statement and five 
items specific to the reporting of NMAs. Although NMA reporting is improving, it is unclear whether PRISMA‑NMA 
has accelerated this improvement. We aimed to investigate the impact of PRISMA‑NMA and highlight key items that 
require attention and improvement.
Methods: We updated our previous collection of NMAs with articles published between April 2015 and July 2018. 
We assessed the completeness of reporting for each NMA, including main manuscript and online supplements, using 
the PRISMA‑NMA checklist. The PRISMA‑NMA checklist originally includes 32 total items (i.e. a 32‑point scale original 
PRISMA‑NMA score). We also prepared a modified version of the PRISMA‑NMA checklist with 49 items to evaluate 
separately at a more granular level all multiple‑content items (i.e. a 49‑point scale modified PRISMA‑NMA score). We 
compared average reporting scores of articles published until and after 2015.
Results: In the 1144 included NMAs the mean modified PRISMA‑NMA score was 32.1 (95% CI 31.8–32.4) of a pos‑
sible 49‑excellence‑score. For 1‑year increase, the mean modified score increased by 0.96 (95% CI 0.32 to 1.59) for 389 
NMAs published until 2015 and by 0.53 (95% CI 0.02 to 1.04) for 755 NMAs published after 2015. The mean modified 
PRISMA‑NMA score for NMAs published after 2015 was higher by 0.81 (95% CI 0.23 to 1.39) compared to before 2015 
when adjusting for journal impact factor, type of review, funding, and treatment category. Description of summary 
effect sizes to be used, presentation of individual study data, sources of funding for the systematic review, and role of 
funders dropped in frequency after 2015 by 6–16%.
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Background
The Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement was developed 
to promote comprehensive reporting in published sys-
tematic reviews with narrative summary and pairwise 
meta-analysis to increase transparency and reproduc-
ibility [1]. The PRISMA statement, published in 2009, 
was initially designed for systematic reviews and pairwise 
meta-analyses of healthcare interventions and has been 
widely used by reviewers and journals [2]. The statement 
was updated to PRISMA 2020 to reflect recent advances 
in the methods of systematic reviews [3]. It is of critical 
importance to report sufficient and accessible informa-
tion so that research can be reproduced, which can help 
avoiding biased recommendations and distort health-
care decision making [4, 5].
The PRISMA extension for network meta-analysis 
(NMA), published in 2015, was prompted by empiri-
cal research showing that reporting of NMA was prob-
lematic [6]. Our previous scoping reviews including 456 
NMAs published until 2015 showed that only a quarter 
of NMAs were of high methodological quality and that 
half of the NMAs had failed to report the prerequi-
site assumptions of evidence synthesis, although both 
reporting and methodology were found to be improving 
over time [7, 8]. The PRISMA extension provides guid-
ance for reporting of systematic reviews with NMA and 
highlights their key reporting components, aiming to 
improve primarily reporting and indirectly the conduct 
of reviews with NMA. There are five additional items in 
the PRISMA extension to NMA: description of meth-
ods used to explore network geometry, description of 
methods used to assess inconsistency, presentation of 
network diagram, brief overview of network character-
istics, and description of results from investigations of 
inconsistency.
There are few empirical studies that have evaluated the 
completeness of reporting of NMAs since the publication 
of the PRISMA extension. The assessment of reporting of 
21 systematic reviews with NMAs published until 2017 
using the PRISMA-NMA checklist showed that report-
ing was low in the dental care field [9]. Tonin et al. [10] 
assessed the extend of compliance with PRISMA (for 
NMAs published before 2015) and PRISMA-NMA (for 
NMAs published between 2015 and end of 2016) in 477 
NMAs of pharmacological treatments and showed minor 
improvement in reporting according to the PRISMA 
score. A scoping review of 89 NMAs with complemen-
tary and alternative medicines published up until 2018 
showed that the PRISMA-NMA guideline was overall 
adequately adopted through key reporting items such as 
the existence of a protocol, exploring network geometry, 
and risk of bias assessment were often missing (up to 
65%) [11].
As previous empirical research has suggested that 
reporting of NMAs is improving over time, it is unclear 
whether the PRISMA-NMA statement has acceler-
ated this improvement. Our objective was to empiri-
cally assess whether the PRISMA-NMA statement had 
an important impact on the completeness of reporting 
by comparing NMA articles of randomised controlled 
trials (RCTs) between two time periods (2013–2015 
and 2016–2018). We also aim to investigate publication 
features (such as journal characteristics or the exist-
ence of a protocol) and network characteristics (such 
as type of interventions compared) that might modify 
the completeness of reporting. We additionally sought 
to highlight key items that require further attention and 
potential improvement moving forward.
Methods
Eligibility criteria and study selection
We updated our previous collection of NMAs with 
articles published between April 2015 and July 2018 
using the same search strategy and inclusion criteria as 
described in our previously published reviews [7, 8, 12]. 
In brief, networks were eligible if they included RCTs 
only, included at least four treatment nodes in the net-
work, they had conducted any form of valid indirect 
comparison or NMA, and the number of studies was 
larger than the number of treatments compared (see 
also Appendix 1). In the present study, we included arti-
cles published between 2013 and 2018, to have an equal 
chronological timeframe before and after the PRISMA-
NMA publication (published in June 2015).
Data abstraction
We developed a predefined data abstraction form in 
REDCap [13]. We included first author’s name, publica-
tion year, journal name, and country of corresponding 
author in the abstracted data. We denoted each journal’s 
impact factor as indicated in the Web of Science (year 
Conclusions: NMAs published after 2015 more frequently reported the five items associated with NMA compared 
to those published until 2015. However, improvement in reporting after 2015 is compatible with that observed on a 
yearly basis until 2015, and hence, it could not be attributed solely to the publication of the PRISMA‑NMA.
Keywords: Multiple treatment meta‑analysis, PRISMA‑NMA, Systematic review, Reporting
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2019). Impact factors for journals not included in this list 
were obtained from the relevant journals’ official web-
site. If an impact factor was not available for year 2019, 
it was retrieved from a previous year. We grouped NMAs 
according to the type of treatment comparisons that were 
presented (pharmacological vs placebo, pharmacologi-
cal vs pharmacological or non-pharmacological vs any 
intervention) [12]. If a network included pharmacological 
interventions and a placebo or control, then it was clas-
sified as pharmacological vs placebo/control comparison 
type. Networks with pharmacological treatments but no 
placebo or control were categorised as a pharmacological 
vs pharmacological comparison type. Networks includ-
ing at least one non-pharmacological treatment were 
classified as non-pharmacological vs any intervention 
comparison type. We classified NMAs according to the 
structure of the network (i.e. open networks vs networks 
with at least one closed loop of evidence) and the type of 
analyses presented (Bayesian, frequentist, or both). We 
also categorised NMAs according to their type of fund-
ing, irrespective of authors’ funding, as industry-spon-
sored, publicly sponsored, mixed-funded, non-sponsored 
studies, and funding not reported.
We assessed the completeness of reporting for each 
NMA, including main manuscript and online sup-
plements, using the PRISMA-NMA checklist, which 
includes 32 items in total: 27 core items as indicated in 
the core 2009 PRISMA Statement and five additional 
items (S1-S5) specific to the reporting of NMAs. We 
also prepared a modified version of the PRISMA-NMA 
checklist such that multiple items could be listed an eval-
uated separately at a more granular level, which resulted 
in 49 items (Appendix Table 1); this included for exam-
ple two separate terms for systematic review and NMA/
related form of meta-analysis in the title, instead of a sin-
gle item. We assigned each component a ‘yes’ (1 point) 
or ‘no’ (0 points) depending on whether it was reported. 
We ended up with a scale of 32 points for the original 
PRISMA-NMA items (termed ‘original PRISMA-NMA 
score’) and a scale of 49 points for the modified checklist 
(‘modified PRISMA-NMA score’).
Statistical analysis
We compared reporting scores (both original and 
modified PRISMA-NMA scores, as described in the 
data abstraction section) between NMAs published in 
the interval January 2013 to December 2015 and Janu-
ary 2016 to December 2018. We performed a descrip-
tive analysis for the PRISMA-NMA items (reporting 
percentage per item) and presented the percentage of 
studies with adequate reporting for each item prior to 
and after the PRISMA-NMA publication. We evaluated 
whether there was a total improvement in reporting 
over publication year using the Cox and Stuart trend 
test (null hypothesis: there is not a monotonic trend) in 
the trend library in R [14].
We compared reporting scores between Cochrane 
NMAs, non-Cochrane NMAs with a protocol, and non-
Cochrane NMAs without a protocol. In non-Cochrane 
NMAs, we considered a protocol to be available only 
when this was reported in the manuscript (including 
registration in PROSPERO). Reporting scores were 
additionally compared between journals endorsing 
the original PRISMA and journals that did not recom-
mend using PRISMA in their submission guidelines, as 
reported in http:// www. prisma- state ment. org/ Endor 
sement/ PRISM AEndo rsers. We calculated the mean 
percent score difference between 2013 and 2015 and 
2016 and 2018 along with a 95% confidence interval 
(CI) per journal with impact factor > 10. We also cal-
culated the mean and median scores for each scale, 
along with the 95% CI or interquartile range (IQR), 
respectively.
We conducted a univariable regression analysis assess-
ing the overall impact of year of publication as a dichoto-
mous variable until vs. after 2015 on the PRISMA-NMA 
score. We also performed two univariable regression 
analyses to assess the impact of year of publication on 
the PRISMA-NMA score, for studies published before 
and after 2015, separately. Similarly, we performed a uni-
variable regression for studies published until and after 
the PRISMA-NMA publication focusing only on the 
NMA specific items S1-S5 (min score 0, max score 5). To 
evaluate jointly the influence of the journal impact fac-
tor, year of publication, treatment type (pharmacologi-
cal vs. non-pharmacological), funding type (industry or 
mixed vs. other), and review type (review with protocol 
vs. review without protocol) on reporting scores, we per-
formed a multivariable regression analysis model. In case 
the impact factor was not available for a journal, we con-
sidered it as a zero value. We labelled the treatment type 
pharmacological when the network was categorised as 
pharmacological vs placebo/control or as pharmacologi-
cal vs pharmacological comparison type, and the non-
pharmacological treatment type when the network was 
categorised as non-pharmacological vs any. A network 
had an industry or mixed funding type when at least one 
of the sponsors for the review itself was industry. Each 
review was also classified depending on the protocol 
availability. We decided to use a binary categorisation 
of each covariate to improve power in our analysis. We 
also performed a multivariable regression using the same 
covariates apart from year of publication, which was con-
sidered as a dichotomous variable until vs. after 2015, as 
a subsequent sensitivity analysis. For our analyses, we 
used both original and modified PRISMA-NMA scores, 
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a significance level of 5%, and the R software version 3.6.2 
(R Development Core Team 2019) [15].
Results
Literature search
The updated literature search yielded 4871 citations 
(Fig. 1). We included an additional of 489 citations pub-
lished between 2013 and 2018 from supplementary 
sources and our published scoping reviews [7, 8, 12]. 
After de-duplication (i.e. multiple publications of the 
same systematic review and NMA), we screened 4446 
unique titles and abstracts and 2212 full-text citations. 
Overall, we included 1144 NMAs that fulfilled the eligi-
bility criteria (Appendix Table 2).
In the following, NMA reporting is presented accord-
ing to the modified PRISMA-NMA score. Results accord-
ing to the original PRISMA-NMA score are presented in 
the supplementary files.
Study and method characteristics
The number of NMAs published by year between 2013 
and 2018 along with the per-year average score across 
years is shown in Fig.  2 (see also Appendix Fig.  1 for 
the original PRISMA-NMA score). The highest mean 
reporting score was observed in 2018, whereas the 66% 
of the NMAs (755 of 1144 NMAs) were published in 
2016–2018. The majority of the corresponding authors 
had an affiliation with China (357, 31%), the USA (184, 
16%), and the UK (164, 14%) (Table 1, Appendix Fig. 2). 
Of the 450 journals included in our database, only 33 had 
already adopted the original PRISMA guidance. NMAs 
were published in journals with a median impact fac-
tor of 3.74 (IQR 2.69–5.81; Appendix Fig. 3). Among the 
included reviews, 801 (70%) NMAs employed a Bayesian 
hierarchical approach alone (779, 68%) or in addition to 
a frequentist approach (22, 2%). Most networks included 
pharmacological treatments only or in addition to a pla-
cebo/control treatment (907, 79%). We identified 33 
Cochrane reviews with a protocol (3% of the networks), 
280 non-Cochrane reviews with a protocol (24% of the 
networks), and 831 non-Cochrane reviews without a pro-
tocol (73% of the networks).
Five in six networks included at least one closed loop 
of evidence (958, 84%). A total of 398 NMAs (35%) were 
publicly funded, but funding was not reported in 314 
(27%) NMAs. The most popular journals in our NMA 
database were PLOS ONE (n = 52, 5%) followed by Onco-
target (43; 4%) and Medicine (42; 4%).
Fig. 1 Flow diagram of the selection process for the included systematic reviews and network meta‑analyses
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Comprehensiveness of reporting in network meta‑analyses
Reporting score overall, until and after 2015
The modified PRISMA-NMA of 49 items had a mean 
score 32.1 (95% CI 31.8–32.4; Appendix Fig. 4a; Appen-
dix Fig.  5a). The mean score of NMAs published until 
and after 2015 were 31.3 (95% CI 30.8–31.8) and 32.6 
(95% CI 32.2–33.0) (Appendix Figs. 4b and 5b). Although 
reporting score increased per year across NMAs, the 
increase was small and not statistically significant (trend 
test p-value = 0.480, Appendix Fig. 6).
Findings from univariable regression analysis showed 
that after 2015 reporting of NMAs improved by an aver-
age score of 1.25 (95% CI 0.59 to 1.91; Table 2). Univari-
able regression analysis showed that the PRISMA-NMA 
score until 2015 is positively associated with year, and for 
1-year increase the score increases by 0.96 items (95% 
CI 0.32 to 1.59). For NMAs published after 2015, the 
score increases by 0.53 (95% CI 0.02 to 1.04) for 1-year 
increase. Focusing only on the NMA-specific items 
S1-S5, the speed of improvement was higher before the 
publication of the PRISMA-NMA guidelines (average 
per-year score increase in items S1–S5: 2013–2015 0.32 
95% CI 0.14 to 0.49; 2016–2018 0.22 95% CI 0.11 to 0.33; 
Appendix Table 3).
Factors that impact on reporting
On average, articles published in journals endorsing the 
original PRISMA had higher modified score (mean 34.5, 
95% CI 33.8–35.2) compared with articles published 
in journals not explicitly endorsing PRISMA (median 
31.7, IQR 21.4–32.0), yet this is not substantial (Fig. 3c; 
Appendix Fig. 4c). Overall, reporting of NMAs has been 
improved within each journal after 2015 (Appendix 
Table 4). Reporting did not vary substantially across con-
tinents (Appendix Fig. 7(c)(d)). Reporting differed across 
the types of reviews, with Cochrane reviews being asso-
ciated with the highest scores (Cochrane reviews: mean 
36.8, 95% CI 35.6–38.0; non-Cochrane reviews with 
protocol: mean 36.2, 95% CI 35.7–36.7; non-Cochrane 
reviews without a protocol median 30.6, 95% CI 29.8–
30.4, Appendix Fig. 7(i)(j)).
Findings from multivariable regression analysis includ-
ing year as a continuous variable showed that there was 
an increase in PRISMA score per year by 0.34 items 
(95% CI increase 0.16 to 0.52) when adjusting for jour-
nal impact factor, type of review, funding, and treatment 
types being compared in the network. Reporting was 
analogous to the journal impact factor (average score-
increase 0.10 items, 95% CI increase 0.07 to 0.13). A 
positive association was also observed with publicly/non-
sponsored NMAs (average score-increase 1.34 items, 
95% CI increase 0.56 to 2.11; mean score: 32.5, 95% CI 
32.2–32.8). Findings from multivariable regression anal-
ysis including year as a binary variable (before and after 
2015) were in agreement with the multivariable regres-
sion and the year as a continuous variable, and suggested 
that there was an improvement in PRISMA score after 
2015 by 0.81 items (95% CI increase 0.23 to 1.39) when 
adjusting for journal impact factor, type of review, fund-
ing, and treatment types being compared in the network. 
Conversely, a negative association was observed between 
the PRISMA-NMA score and reviews without a protocol 
Fig. 2 Number of systematic reviews and network meta‑analyses, and per‑paper average modified PRISMA‑NMA score published between 2013 
and 2018 ‘*’ denotes that the search was performed up to July 2018, and thus only 7 months of that year are reflected in this graph. Error bars 
parallel to the y‑axis represent the uncertainty of the modified PRISMA‑NMA score
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Table 1 Characteristics of NMAs published between 2013 and 2018
Published in journals endorsing NMA NMAs published between 
2013 and 2015
NMAs published between 
2016 and 2018
Total
Yes No Total Yes No Total Yes No Total
88 (23%) 301 (77%) 389 82 (11%) 673 (89%) 755 170 (15%) 974 (85%) 1144
Ten most prevalent countries of corresponding author: frequency (%)
 China 17 (22%) 60 (78%) 77 21 (8%) 256 (92%) 277 38 (11%) 316 (89%) 354
 USA 17 (22%) 61 (78%) 78 12 (11%) 94 (89%) 106 29 (16%) 155 (84%) 184
 UK 16 (22%) 58 (78%) 74 13 (14%) 77 (86%) 90 29 (18%) 135 (82%) 164
 Canada 10 (29%) 24 (71%) 34 8 (20%) 32 (80%) 40 18 (24%) 56 (76%) 74
 Italy 5 (16%) 26 (84%) 31 4 (13%) 28 (88%) 32 9 (14%) 54 (86%) 63
 Korea (South) 1 (25%) 3 (75%) 4 3 (10%) 28 (90%) 31 4 (11%) 31 (89%) 35
 Germany 3 (20%) 12 (80%) 15 1 (6%) 16 (94%) 17 4 (13%) 28 (88%) 32
 France 2 (20%) 8 (80%) 10 2 (17%) 10 (83%) 12 4 (18%) 18 (82%) 22
 Switzerland 4 (40%) 6 (60%) 10 3 (30%) 7 (70%) 10 7 (35%) 13 (65%) 20
 Japan 2 (40%) 3 (60%) 5 0 (0%) 15 (100%) 15 2 (10%) 18 (90%) 20
Ten most prevalent journals: frequency (%)
 Plos One 31 (100%) NA 31 21 (100%) NA 21 52 (100%) NA 52
 Oncotarget NA 4 (100%) 4 NA 39 (100%) 39 NA 43 (100%) 43
 Medicine NA 9 (100%) 9 NA 33 (100%) 33 NA 42 (100%) 42
 Cochrane Database Of Systematic Reviews NA 16 (100%) 16 NA 17 (100%) 17 NA 33 (100%) 33
 Scientific Reports NA 2 (100%) 2 NA 25 (100%) 25 NA 27 (100%) 27
 Current Medical Research And Opinion NA 11 (100%) 11 NA 10 (100%) 10 NA 21 (100%) 21
 BMJ 16 (100%) NA 16 5 (100%) NA 5 21 (100%) NA 21
 Health Technology Assessment NA 8 (100%) 8 NA 11 (100%) 11 NA 19 (100%) 19
 Alimentary Pharmacology & Therapeutics 8 (100%) NA 8 10 (100%) NA 10 NA 18 (100%) 18
 Clinical Therapeutics NA 7 (100%) 7 NA 8 (100%) 8 NA 15 (100%) 15
Type of review: frequency (%)
 Non‑Cochrane review without protocol 70 (23%) 236 (77%) 306 42 (8%) 483 (92%) 525 112 (13%) 719 (87%) 831
 Non‑Cochrane review with protocol 18 (27%) 49 (73%) 67 40 (19%) 173 (81%) 213 58 (21%) 222 (79%) 280
 Cochrane review 0 (0%) 16 (100%) 16 0 (0%) 17 (100%) 17 0 (0%) 33 (100%) 33
Type of treatment group: frequency (%)
 Pharmacological vs Placebo 44 (20%) 171 (80%) 215 50 (14%) 315 (86%) 365 94 (16%) 486 (84%) 580
 Pharmacological vs Pharmacological 27 (26%) 77 (74%) 104 16 (7%) 207 (93%) 223 43 (13%) 284 (87%) 327
 Non‑pharmacological vs Any treatment 17 (24%) 53 (76%) 70 16 (10%) 151 (90%) 167 33 (14%) 204 (86%) 237
Shape of network: frequency (%)
 Full shaped with at least one closed loop 71 (22%) 245 (78%) 316 69 (11%) 573 (89%) 642 140 (15%) 818 (85%) 958
 Open shaped with no closed loops 17 (24%) 55 (76%) 72 13 (12%) 94 (88%) 107 30 (17%) 149 (83%) 179
 Unclear 0 (0%) 1 (100%) 1 0 (0%) 6 (100%) 6 0 (0%) 7 (100%) 7
Presentation results: frequency (%)a
 Presentation of NMA results
 Ranking statistics 46 (25%) 138 (75%) 363 58 (11%) 494 (89%) 552 104 (14%) 632 (86%) 736
 Forest plot 48 (24%) 149 (76%) 197 60 (12%) 449 (88%) 509 108 (15%) 598 (85%) 706
 League tables 37 (23%) 124 (77%) 161 48 (10%) 419 (90%) 467 85 (14%) 543 (86%) 628
Analysis setting: frequency (%)
 Bayesian 67 (24%) 215 (76%) 272 56 (11%) 441 (89%) 497 123 (16%) 656 (84%) 779
 Frequentist 19 (19%) 79 (81%) 98 26 (11%) 209 (89%) 235 45 (14%) 288 (86%) 333
 Both 0 (0%) 1 (100%) 1 0 (0%) 21 (100%) 21 0 (0%) 22 (100%) 22
 Unclear 2 (25%) 6 (75%) 8 0 (0%) 2 (100%) 2 2 (20%) 8 (80%) 10
Bayesian analysis settings: frequency (%)a
 Bayesian setting
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(average score-decrease 5.18 items, 95% CI decrease 4.55 
to 5.80; mean score 30.6, 95% CI 30.2–30.9), and net-
works including pharmacological treatments (average 
score-decrease 0.71 items 95% CI decrease 0.04 to 1.40; 
mean score 31.8, 95% CI 31.4–32.1; Table  2; Appendix 
Table 3).
PRISMA‑NMA items that improved and items that still need 
attention
The percentage of adequately reported items before 
and after the PRISMA-NMA statement publication 
is presented in Fig.  3. Reporting was improved in 23 
(47%) items, including the five items (S1-S5) specific 
to the reporting of the synthesis in NMAs. Overall, 
of the 958 with at least one closed loop, 693 networks 
(72%) reported consistency investigation, and this has 
improved over the years (range 52–78% NMAs). After 
2015, improvement was also observed in items about the 
overview of the network and study characteristics.
However, reporting of several other items has shown 
little or no improvement after 2015, while adequate 
reporting of some items has declined, signalling a need 
for further attention. Description of summary effect sizes 
to be used, presentation of individual study data, sources 
of funding for the systematic review, and role of funders 
dropped in frequency after 2015 by 6–16% (Fig.  3). In 
particular, the role of funders for the systematic review 
was consistently missing across years for 71–88% NMAs 
(Appendix Table 5). A total of 294 NMAs (26%) reported 
the existence of a protocol, of which 229 (78%) reported a 
registry or a web site where a protocol could be accessed, 
and 79 (34%) of these NMAs reported this information 
in the abstract as well. Details on methods to assess bias 
across studies and on conducting additional analyses 
were underreported across all years.
Discussion
Our findings suggest that key reporting items are miss-
ing in the majority of published NMAs. While minor 
improvements in the reporting of some elements were 
noted following PRISMA-NMA, other elements also 
experienced reductions. In total, reporting has improved 
after 2015 in 47% of the modified PRISMA-NMA items, 
but it has also deteriorated in 49% of the core items. 
Improvement was observed in items about the NMA 
synthesis, overview of the network and study character-
istics, while deterioration was noticed in the description 
of summary effect sizes to be used, presentation of indi-
vidual study data, sources of funding for the systematic 
review, and role of funders.
An explanation of the decrease in inadequately 
reported items may be restriction in the word count 
required by most journals. Also, some of the required 
details may be reported in the study’s protocol. Another 
key item that was inadequately reported was fund-
ing status. Journal guidelines highlight funding as cru-
cial information to be reported in a paper; however, we 
noticed that mainly the author funding is reported and 
a The total number of NMAs does not add up to 1144 as each article might pertain to more than one category
NMA network meta-analysis
Table 1 (continued)
Published in journals endorsing NMA NMAs published between 
2013 and 2015
NMAs published between 
2016 and 2018
Total
Yes No Total Yes No Total Yes No Total
88 (23%) 301 (77%) 389 82 (11%) 673 (89%) 755 170 (15%) 974 (85%) 1144
 Reported prior distributions 37 (24%) 117 (76%) 154 22 (12%) 169 (88%) 191 59 (17%) 286 (83%) 345
 Model fit assessment 40 (26%) 112 (74%) 152 21 (11%) 169 (89%) 190 61 (18%) 281 (82%) 342
 Used different priors as additional analyses 5 (28%) 13 (72%) 18 4 (24%) 13 (76%) 17 9 (26%) 26 (74%) 35
Additional analyses: frequency (%)a
 Additional NMA analyses
 Subgroup and/or sensitivity analysis 50 (28%) 131 (72%) 181 46 (15%) 266 (85%) 312 96 (19%) 397 (81%) 493
 Meta‑regression 18 (26%) 52 (74%) 70 18 (17%) 87 (83%) 105 36 (21%) 139 (79%) 175
 Alternative treatment formulations in the network 13 (42%) 18 (58%) 31 3 (10%) 26 (90%) 29 16 (27%) 44 (73%) 60
Funding: frequency (%)
 Publicly sponsored 27 (21%) 104 (79%) 131 29 (11%) 238 (89%) 267 56 (14%) 342 (86%) 398
 Funding source not reported 8 (9%) 82 (91%) 90 14 (6%) 210 (94%) 224 22 (7%) 292 (93%) 314
 Non‑sponsored 34 (37%) 59 (63%) 93 26 (15%) 143 (85%) 169 60 (23%) 202 (77%) 262
 Industry‑sponsored 16 (24%) 52 (76%) 68 11 (13%) 72 (87%) 83 27 (18%) 124 (82%) 151
 Mixed‑funding 3 (43%) 4 (57%) 7 2 (17%) 10 (83%) 12 5 (26%) 14 (74%) 19
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not funding for the review itself. Funding for the system-
atic review and role of funders are consistently under-
reported, which is a cause of concern. Presentation of 
individual study data is another item that has worsened 
after 2015. This may be because larger and more complex 
networks are being structured compared to past years 
or because of authors’ desire to retain ownership of the 
data, given the large efforts to compile the data sets, and 
to potentially publish new work after additional evidence 
(e.g. treatments) emerge.
Key factors that may impact the reporting were the 
journal’s impact factor, funding type, year of publica-
tion, type of review, and treatment category included in 
the network. In particular, newer and publicly sponsored 
NMAs of non-pharmacological therapies with a proto-
col, and published in high impact factor journals, were 
associated with better reporting. Our results showed 
that reviews with a protocol, and particularly Cochrane 
reviews, were associated with higher PRISMA-NMA 
scores.
Overall, reporting is adequate but not high (mean 
PRISMA-NMA score 32.1; 95% CI 31.8–32.4; max 
49). Authors of NMAs showed a steep improvement 
in earlier years (2013–2015), but it stabilises after the 
PRISMA-NMA guideline publication. The improve-
ment continues to exist throughout the years, but the 
speed of improvement is lower between 2016 and 2018. 
This suggests that overall, the PRISMA-NMA guidance 
Table 2 Univariable and multivariable regression using the modified PRISMA‑NMA
CI confidence interval
Covariates Interpretation of the coefficient Coefficient (95% CI) Sample size
Univariable analyses and subgroups
 Published after 2015 vs until 2015 Average increase in the score after 2015 1.25 (0.59, 1.91) Before 2015: 389
After 2015: 755 Year of publication, subgroup: 
only NMAs published before 2015
Average increase in the score per year 0.96 (0.32, 1.59)
 Year of publication, subgroup: 
only NMAs published after 2015
Average increase in the score per year 0.53 (0.02, 1.04)
Multivariable analyses with year as a continuous variable






 Treatment type Average increase in the score if network 
includes pharmacological treatments
 − 0.66 (− 1.34, 0.02) Pharmacological treatments: 907
Non‑pharmacological treatments (refer‑
ence group): 237
 Funding type Average increase in the score if non‑
sponsored/publicly sponsored
1.34 (0.56, 2.11) Non‑sponsored/publicly sponsored/not 
reported: 974
Industry/mixed sponsored (reference 
group): 170
 Review type Average increase in the score if protocol 
is not available/reported
 − 5.12 (− 5.74, − 4.49) With protocol (reference group): 313
Without protocol: 831
 Impact factor Average increase in the score per impact 
factor increase (1 unit)
0.10 (0.07, 0.13)
Multivariable analyses with year as a dichotomous variable
 Year of publication Average increase in the score per year 0.81 (0.23, 1.39) Before 2015 (reference group):389
After 2015:755
 Treatment type Average increase in the score if network 
includes pharmacological treatments
 − 0.72 (− 1.40, − 0.04) Pharmacological treatments: 907
Non‑pharmacological treatments (refer‑
ence group): 237
 Funding type Average increase in the score if non‑
sponsored/publicly sponsored
1.36 (0.58, 2.14) Non‑sponsored/publicly sponsored/Not 
reported: 974
Industry/mixed sponsored (reference 
group): 170
 Review type Average increase in the score if protocol 
is not available/reported
 − 5.18 (− 5.8, − 4.55) With protocol (reference group): 313
Without protocol: 831
 Impact factor Average increase in the score per impact 
factor increase (1 unit)
0.10 (0.06, 0.13)
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has not importantly affected reporting in new NMAs 
compared to older NMAs. This may be because NMA 
authors in the earlier years 2013–2015 already fol-
lowed existing guidelines for standards of conduct of 
NMA through the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) tools 
[16, 17] and National Institute for Clinical Excellence 
(NICE) Decision Support Unit’s Evidence Synthesis 
Technical Support Documents (TSDs) documents [18]. 
However, we observed improvement in the five items 
(S1–S5) specific to the reporting of the synthesis sec-
tion of an NMA after 2015, ranging between 4 and 
12%. The improvement observed in reporting might be 
attributed at least in part to PRISMA-NMA, but may 
also be due to additional factors, such as the increase 
in registering or publishing of peer-reviewed proto-
cols; protocol existence in NMAs has increased from 
15–39% between 2013 and 2018. Our analysis showed 
that there is a slight improvement in reporting in the 
year 2016 compared to the year 2017 (2016: mean 
modified PRISMA-NMA score 33.0, 95% CI 32.3–33.8; 
2017: mean modified PRISMA-NMA score 31.2, 95% 
CI 30.6–31.8). This may be due to the impact factor of 
the journal that NMAs were published in. The median 
impact factor of the journals the NMAs were published 
Fig. 3 Plot of the percentage of adequately reporting the 49 modified PRISMA‑NMA items overall and according to publication interval 2013–2015 
and 2016–2018. PRISMA items are ordered from least to most well reported irrespective publication year. Statistically significant differences are 
indicated with a bold font. Each cell is coloured according to the reporting using the transformation of three colours: red (0%), yellow (50%), and 
green (100%)
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in 2016 was 3.87 (IQR 2.49–5.56), whereas in 2017 was 
3.50 (IQR 2.63–5.16) (Appendix Fig. 8).
In our database of NMAs, the PRISMA-NMA guide-
line is only endorsed by 7% of the journals in which the 
NMAs were published. This highlights the need for jour-
nals publishing systematic reviews and NMAs to adopt 
the PRISMA-NMA guidelines to improve reporting, and 
to request the checklist upon a manuscript submission. 
Based on our findings, we provide recommendations to 
update the PRISMA-NMA statement to facilitate its use 
by systematic reviewers, journal editors, and peer review-
ers (see the section “Conclusions and recommendations 
for practice”).
To the best of our knowledge, this is the largest review 
assessing the PRISMA extension guideline for NMA in 
more than 1000 systematic reviews and NMAs. Our find-
ings are aligned with previous findings by Hutton et  al. 
[11], who evaluated 89 NMAs of non-pharmacological 
therapies; Tonin et  al. [10] who assessed 477 NMAs of 
pharmacological treatments; and Lee and Shin [9] who 
assessed 21 NMAs in dental care. In agreement with 
assessments in systematic reviews and meta-analyses, 
reporting in the 27 core PRISMA items was suboptimal 
[2]. A previous assessment on reporting of pairwise sys-
tematic reviews and meta-analyses on nursing interven-
tions in patients with Alzheimer’s disease before and 
after PRISMA publication showed an improvement in 
the average core PRISMA items from 17.11 to 20.83 score 
[19]. Our findings about PRISMA-NMA are not limited 
to a specific disease area and showed that the average 
core PRISMA items score did not importantly change 
before (19.58 items) and after 2015 (19.88 items).
In addition to assessing the PRISMA-NMA items in 
the included systematic reviews, we explored factors that 
play a key role in reporting of NMA. In agreement with 
Zarin et  al. [7], we found that the prerequisite assump-
tions are not always considered; 28% of NMAs (265 of 
958 NMAs with a closed loop) did not report an assess-
ment for consistency in their methods. However, similar 
to Petropoulou et al.’s [8] findings, reporting improved a 
bit over the years.
A limitation of our study is that in our assessment we 
considered that a PRISMA component was reported only 
if relevant information was present in the underlying 
section of the manuscript, as indicated in the PRISMA-
NMA guideline. Also, protocols were not assessed for 
reporting relevant details, since the PRISMA-NMA 
guideline refers only to the final manuscript for NMAs. 
In our study, we have not explored differences in NMAs 
pointing authors to the relevant protocols for methods 
details and the remaining NMAs. However, in our assess-
ment, we considered all available supplementary files 
and appendices. Although we may have missed some 
details reported in the protocol, we expect that this could 
not importantly impact our results. Also, an important 
unmeasured confounder in reporting may have been 
journals with no word count restrictions, but we have not 
assessed this further. Another potential limitation is that 
our literature search was conducted up to July 2018, and 
we may have missed recently published NMAs that were 
reported well. Also, the impact of the PRISMA-NMA 
guideline may not immediately be seen in the report-
ing of published NMAs and may take more time to start 
using it. However, this is the largest NMA database that 
assessed reporting, and we expect that no major differ-
ences would be seen in our results regarding the overall 
trend in reporting. A risk of confounding may be associ-
ated with our results between industry-sponsored stud-
ies and pharmacological treatments. We found that both 
factors were associated with a decrease in reporting (of 
the 170 industry-sponsored NMAs, 162 [95%] included 
pharmacological interventions only [with or without a 
placebo] in the network). We used a binary system (pres-
ence/absence) for the PRISMA-NMA items, but this may 
not be the best approach to assess adequacy of report-
ing. For example, authors may report that transitivity was 
assessed but without providing more details on this.
Conclusions and recommendations for practice
NMAs published after 2015 more frequently reported the 
five items associated with NMA (i.e. description of meth-
ods to explore network geometry, description of meth-
ods to assess inconsistency, network plot presentation, 
brief overview of network characteristics, description of 
results from investigations of inconsistency). However, 
several important items are underreported and the yearly 
improvement in reporting is small.
In conducting this research, we chose to split certain 
PRISMA-NMA items into more specific items for eval-
uation, moving from 32 to 49 items. This allowed us to 
highlight crucial aspects of NMA that were or were not 
reported across the years. To this end, we suggest that the 
PRISMA-NMA checklist be updated using the 49 items 
instead of the initially suggested 32 items. This will pro-
vide more in-depth guidance to review authors, review-
ers, editors, and readers for adequate reporting in NMA. 
The 49 items are listed in Appendix Table  1. Clarifying 
the information presented in the PRISMA-NMA 32 
items into 49 different items may increase word count, 
but will enhance transparency of reporting. Online 
appendix files can also be used for additional and sup-
porting information of the systematic review and NMA.
The original or modified PRISMA-NMA guidelines 
should be used extensively by review authors and be 
adopted by a wider range of journals. Journals editors, 
peer-reviewers, and systematic review authors should use 
Page 11 of 12Veroniki et al. Syst Rev          (2021) 10:246  
the PRISMA-NMA list on a regular basis to write evalu-
ate and publish results from NMA, paying special atten-
tion to items that are still underreported as highlighted 
in Fig. 3.
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